Depletion of substance P, a mechanism for inhibition of mouse scratching behavior by tacrolimus

European Journal of Pharmacology

Volumn 626, Issue 2-3, 2010, Pages 283-289

  Inagaki, Naoki ^a   Shiraishi, Noriko ^a   Igeta, Katsuhiro ^a   Nagao, Masafumi ^a   Kim, John Fan ^a   Chikumoto, Takao ^a   Itoh, Tomokazu ^a   Katoh, Hideo ^a   Tanaka, Hiroyuki ^a   Nagai, Hiroichi ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Allergic dermatitis; Dexamethasone; Hapten; IgE; Interferon ; Interleukin 4; Mouse scratching behavior; Substance P; Tacrolimus

Indexed keywords

DEXAMETHASONE; GAMMA INTERFERON; IMMUNOGLOBULIN G; INTERLEUKIN 4; MESSENGER RNA; N BENZYL N2 [4 HYDROXY 1 [(1 METHYL 1H INDOL 3 YL)CARBONYL]PROLYL] N METHYL 3 (2 NAPHTHYL)ALANINAMIDE; SUBSTANCE P; TACROLIMUS;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BIOACCUMULATION; CONTROLLED STUDY; DRUG MECHANISM; EAR DISEASE; EOSINOPHIL; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; SCRATCHING; SKIN ALLERGY; SKIN PRURITUS; SKIN SWELLING;

ANIMALS; BEHAVIOR, ANIMAL; DERMATITIS, ATOPIC; DEXAMETHASONE; EAR; MALE; MICE; MICE, INBRED BALB C; PRURITUS; SUBSTANCE P; TACROLIMUS;

EID: 70649084979     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.09.043     Document Type: Article

References (35)

1. 1 tachykinin receptors in mice. J. Pharmacol. Exp. Ther. 286 (1998) 1140-1145
2. Barnetson R.S., and White A.D. The use of corticosteroids in dermatological practice. Med. J. Aust. 156 (1992) 428-431
3. Bieber T. Topical tacrolimus (FK 506): a new milestone in the management of atopic dermatitis. J. Allergy Clin. Immunol. 102 (1998) 555-557
4. Cheer S.M., and Plosker G.L. Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis. Am. J. Clin. Dermatol. 2 (2001) 389-406
5. + cells. J. Immunol. 146 (1991) 2374-2381
6. Foreman J.C. The skin as an organ for the study of the pharmacology of neuropeptides. Skin Pharmacol. 1 (1988) 77-83
7. 1 receptor antagonist, FK888. Br. J Pharmacol. 107 (1992) 785-789
8. Furue M., Furukawa F., Hide M., and Takehara K. Guidelines for therapy for atopic dermatitis 2004. Jpn. J. Dermatol. 114 (2004) 135-142
9. Hirano T., Yamakawa N., Miyajima H., Maeda K., Takai S., Ueda A., Taniguchi O., Hashimoto H., Hirose S., Okumura K., and Ovary Z. An improved method for the detection of IgE antibody of defined specificity by ELISA using rat monoclonal anti-IgE antibody. J. Immunol. Methods 119 (1989) 145-150
10. Hoffman D.R., Yamamoto F.Y., Geller B., and Haddad Z. Specific IgE antibodies in atopic eczema. J. Allergy Clin. Immunol. 55 (1975) 256-267
11. Inagaki N., Igeta K., Kim J.F., Nagao M., Shiraishi N., Nakamura N., and Nagai H. Involvement of unique mechanisms in the induction of scratching behavior in BALB/c mice by compound 48/80. Eur. J. Pharmacol. 448 (2002) 175-183
12. Inagaki N., Igeta K., Shiraishi N., Kim J.F., Nagao M., Nakamura N., and Nagai H. Evaluation and characterization of mouse scratching behavior by a new apparatus, MicroAct. Skin Pharmacol. Appl. Skin Physiol. 16 (2003) 165-175
13. Inagaki N., Shiraishi N., Igeta K., Itoh T., Chikumoto T., Nagao M., Kim J.F., and Nagai H. Inhibition of scratching behavior associated with allergic dermatitis in mice by tacrolimus, but not be dexamethasone. Eur. J. Pharmacol. 546 (2006) 189-196
14. Katoh N., Hirano S., Yasuno H., and Kishimoto S. Effects of tacrolimus ointment on facial eruption, itch, and scratching in patients with atopic dermatitis. J. Dermatol. 31 (2004) 194-199
15. Kitagaki H., Ono N., Hayakawa K., Kitazawa T., Watanabe K., and Shiohara T. Repeated elicitation of contact hypersensitivity induces a shift in cutaneous cytokine milieu from a T helper cell type 1 to a T helper cell type 2 profile. J. Immunol. 159 (1997) 2484-2491
16. Leung A.K., and Barber K.A. Managing childhood atopic dermatitis. Adv. Ther. 20 (2003) 129-137
17. Maekawa T., Nojima H., Kuraishi Y., and Aisaka K. The cannabinoid CB2 receptor inverse agonist JTE-907 suppresses spontaneous itch-associated responses of NC mice, a model of atopic dermatitis. Eur. J. Pharmacol. 542 (2006) 179-183
18. Miyayasu K., Mak J.C., Nishikawa M., and Barnes P.J. Characterization of guinea pig pulmonary neurokinin type 1 receptors using a novel antagonist ligand, [3H]FK888. Mol. Pharmacol. 44 (1993) 539-544
19. Nagai H., Hiyama H., Matsuo A., Ueda Y., Inagaki N., and Kawada K. FK-506 and cyclosporin A potentiate the IgE antibody production by contact sensitization with hapten in mice. J. Pharmacol. Exp. Ther. 283 (1997) 321-327
20. Nagai H., Matsuo A., Hiyama H., Inagaki N., and Kawada K. Immunoglobulin E production in mice by means of contact sensitization with a simple chemical, hapten. J. Allergy Clin. Immunol. 100 (1997) S39-44
21. Nakagawa H., Etoh T., Ishibashi Y., Higaki Y., Kawashima M., Torii H., and Harada S. Tacrolimus ointment for atopic dermatitis. Lancet 344 (1994) 883
22. Nakano T., Andoh T., Tayama M., Kosaka M., Lee J.B., and Kuraishi Y. Effects of topical application of tacrolimus on acute itch-associated responses in mice. Biol. Pharm. Bull. 31 (2008) 752-754
23. Ruzicka T., Bieber T., Schöpf E., Rubins A., Dobozy A., Bos J.D., Jablonska S., Ahmed I., Thestrup-Pedersen K., Daniel F., Finzi A., and Reitamo S. A short-term trial of tacrolimus ointment for atopic dermatitis. European tacrolimus multicenter atopic dermatitis study group. N. Engl. J. Med. 337 (1997) 816-821
24. Sampson H.A., and Albergo R. Comparison of results of prick skin tests, RAST, and double-blind placebo-controlled food challenges in children with atopic dermatitis. J. Allergy Clin. Immunol. 74 (1984) 26-33
25. Scholzen T., Armstrong C.A., Bunnett N.W., Luger T.A., Olerud J.E., and Ansel J.C. Neuropeptides in the skin: interactions between the neuroendocrine and the skin immune systems. Exp. Dermatol. 7 (1998) 81-96
26. Singalavanija S., Noppakun N., Limpongsanuruk W., Wisuthsarewong W., Aunhachoke K., Chunharas A., Wananukul S., and Akaraphanth R. Efficacy and safety of tacrolimus ointment in pediatric patients with moderate to severe atopic dermatitis. J. Med. Assoc. Thai. 89 (2006) 1915-1922
27. Sperr W.R., Agis H., Czerwenka K., Virgolini I., Bankl H.C., Müller M.R., Zsebo K., Lechner K., and Valent P. Effects of cyclosporine A and FK-506 on stem cell factor-induced histamine secretion and growth of human mast cells. J. Allergy Clin. Immunol. 98 (1996) 389-399
28. Ständer S., and Luger T.A. Antipruritic effects of pimecrolimus and tacrolimus. Hautarzt 54 (2003) 413-417
29. Ständer S., Schürmeyer-Horst F., Luger T.A., and Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Ther. Clin. Risk Manag. 2 (2006) 213-218
30. Ständer S., Ständer H., Seeliger S., Luger T.A., and Steinhoff M. Topical pimecrolimus and tacrolimus transiently induce neuropeptide release and mast cell degranulation in murine skin. Br. J. Dermatol. 156 (2007) 1020-1026
31. Takano N., Arai I., Hashimoto Y., and Kurachi M. Evaluation of antipruritic effects of several agents on scratching behavior by NC/Nga mice. Eur. J. Pharmacol. 495 (2004) 159-165
32. Tanaka A., Muto S., Jung K., Itai A., and Matsuda H. Topical application with a new NF-kappaB inhibitor improves atopic dermatitis in NC/NgaTnd mice. J. Invest. Dermatol. 127 (2007) 855-863
33. Thomsen J.S., Sonne M., Benfeldt E., Jensen S.B., Serup J., and Menne T. Experimental itch in sodium lauryl sulphate-inflamed and normal skin in humans: a randomized, double-blinded, placebo-controlled study of histamine and other inducers of itch. Br. J. Dermatol. 146 (2002) 792-800
34. Wahlgren C.F. Pathophysiology of itching in urticaria and atopic dermatitis. Allergy 47 (1992) 65-75
35. Wahlgren C.F. Itch and atopic dermatitis: an overview. J. Dermatol. 26 (1999) 770-779